Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 685


Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.

Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, Jackson G, Braunwald E; PROVE IT-TIMI 22 Investigators..

J Am Coll Cardiol. 2005 Oct 18;46(8):1405-10.


Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).

Brilakis ES, de Lemos JA, Cannon CP, Wiviott SD, Murphy SA, Morrow DA, Sabatine MS, Banerjee S, Blazing MA, Califf RM, Braunwald E.

Am J Cardiol. 2008 Sep 1;102(5):552-8. doi: 10.1016/j.amjcard.2008.04.024. Epub 2008 Jun 12.


Intensive versus moderate lipid lowering with statins after acute coronary syndromes.

Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators..

N Engl J Med. 2004 Apr 8;350(15):1495-504. Epub 2004 Mar 8. Erratum in: N Engl J Med. 2006 Feb 16;354(7):778.


Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy.

Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E; PROVE IT-TIMI 22 Investigators..

J Am Coll Cardiol. 2005 Oct 18;46(8):1411-6. Erratum in: J Am Coll Cardiol. 2006 Jan 17;47(2):472.


Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.

Ray KK, Cannon CP, Cairns R, Morrow DA, Rifai N, Kirtane AJ, McCabe CH, Skene AM, Gibson CM, Ridker PM, Braunwald E; PROVE IT-TIMI 22 Investigators..

J Am Coll Cardiol. 2005 Oct 18;46(8):1417-24.


Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: the CHILLAS study.

Zhao SP, Peng DQ, Yu BL, Huo Y; CHILLAS investigators..

Am Heart J. 2009 Oct;158(4):509-512.e1. doi: 10.1016/j.ahj.2009.07.030.


Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology.

Ray KK, Cannon CP.

Curr Opin Lipidol. 2004 Dec;15(6):637-43. Review.


Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial).

Pedersen TR, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Lindahl C, Szarek M.

Am J Cardiol. 2010 Aug 1;106(3):354-9. doi: 10.1016/j.amjcard.2010.03.033.


Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy.

Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E.

J Am Coll Cardiol. 2006 Aug 1;48(3):438-45. Epub 2006 Jul 12.


Early time to benefit with intensive statin treatment: could it be the pleiotropic effects?

Ray KK, Cannon CP.

Am J Cardiol. 2005 Sep 5;96(5A):54F-60F. Review.


Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE).

Deedwania P, Stone PH, Bairey Merz CN, Cosin-Aguilar J, Koylan N, Luo D, Ouyang P, Piotrowicz R, Schenck-Gustafsson K, Sellier P, Stein JH, Thompson PL, Tzivoni D.

Circulation. 2007 Feb 13;115(6):700-7. Epub 2007 Feb 5.


Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events.

Arca M, Gaspardone A.

Drugs. 2007;67 Suppl 1:29-42. Review.


Supplemental Content

Support Center